Cardiomyopathy

Recent advances in gene-silencing and gene-editing therapies have demonstrated significant potential in altering the treatment landscape for transthyretin (TTR) amyloidosis, transforming the disease’s perception from universally progressive and fatal to treatable with highly specific and effective therapies. Gene-silencing and gene-editing therapies have led to substantial improvement in outcomes for patients with ATTR polyneuropathy. Small-scale studies...

The infiltration of left atria in patients with ATTR-CM can have various effects, all of which can be tracked in different ways. This study provides some insight into how it can be tracked, and its clinical significance. The involvement of left atrial pathology in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) is of significant clinical interest....

The rate of systemic embolism among patients with ATTR-CM is not well-researched, and this study aims to understand how this complication correlates with other common factors affecting this population. Among patients with transthyretin amyloid cardiomyopathy (ATTR-CM), systemic embolism is a possible complication. However, data about the prevalence of systemic embolism in this population are scarce,...

Predicting which patients may have ATTR-CM can be complicated and this study attempts to develop a simple and useful way to determine which patients would benefit from further ATTR-CM testing. Transthyretin amyloid cardiomyopathy (ATTR-CM) can drastically decrease patients’ life expectancies and quality of life, so determining which patients are at risk of this disease is...

Tafamidis has been shown to provide increased life expectancy and quality of life in patients with ATTR-CM. This study further quantified these findings. The Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) successfully illustrated that tafamidis reduced mortality and cardiovascular-related hospitalizations in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). A recent study, published in the European Heart...

ATTR-CM treatment is difficult, in most cases, but diflunisal is a promising treatment option for wild-type ATTR-CM. Treatment options for transthyretin amyloid cardiomyopathy (ATTR-CM) have historically been either risky or lacking in long-term efficacy. Treating ATTR-CM is, in most cases, significantly improved when it is discovered early, although this poses some unique challenges of its...

With a minimal incidence of amyloid recurrence in the cardiac allograft, cardiac transplantation is well tolerated, increases functional ability, and lengthens survival in patients with ATTR-CM, according to a 30-year retrospective study. ATTR-CM should be included in the list of transplantation indications. Cardiomyopathy caused by transthyretin amyloidosis cardiomyopathy (ATTR-CM) is progressive and fatal. Patients with...

In patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), tafamidis was associated with a lower rate of CV-related hospitalizations and a shorter stay. Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is an underdiagnosed disease characterized by deposits of improperly folded transthyretin amyloid fibrils, resulting in end-organ dysfunction. ATTR-CM patients present with symptoms of invasive cardiomyopathy and heart failure necessitating expensive...

Emboli are a common complication of amyloid transthyretin cardiomyopathy (ATTR-CM). This study found that the CHA2DS2-VASc score is not useful in predicting embolic events in ATTR-CM patients with or without AF, and that VKAs and DOACs are equally effective in preventing embolism, in this scenario. Transthyretin amyloid cardiomyopathy (ATTR-CM) is an infiltrative illness with a...